Winkler U H, Howie H, Bühler K, Korver T, Geurts T B, Coelingh Bennink H J
Department of Obstetrics and Gynaecology, University Hospital of Essen, Germany.
Contraception. 1998 Jun;57(6):385-92. doi: 10.1016/s0010-7824(98)00045-6.
The effects of two progestogen-only pills containing either 75 microgram desogestrel (DSG) or 30 microgram levonorgestrel (LNG) on hemostasis were investigated in a double-blind, randomized, controlled study of seven treatment cycles in 78 healthy women. DSG reduced factor VII activity (p < 0.05) and prothrombin fragment 1+2 (p < 0.05) and increased protein S (p < 0.001). LNG reduced factor VII activity (p < 0.01) and plasminogen activity (p < 0.01) and increased tissue-plasminogen activator (t-PA) (p < 0.05). At the end of the post-treatment cycle with DSG, protein S (p < 0.01) and t-PA (p < 0.05) were increased and plasminogen activity was decreased (p < 0.05), whereas with LNG, t-PA was increased (p < 0.001) and prothrombin fragment 1+2 (p < 0.05) and plasminogen activity (p < 0.001) were decreased. Between-group comparisons revealed higher values for DSG regarding the anticoagulatory parameter protein S at cycle 7 (p < 0.01) and post-treatment assessments (p < 0.05), and the fibrinolytic parameter plasmin-antiplasmin complex was higher with DSG at cycle 7 (p < 0.05) and at post-treatment (p < 0.05). Both preparations had comparable and potentially favorable effects of hemostasis, and may offer suitable hormonal contraception to women with a personal or family history of venous thromboembolic diseases.
在一项针对78名健康女性进行的为期七个治疗周期的双盲、随机、对照研究中，调查了两种分别含有75微克去氧孕烯（DSG）或30微克左炔诺孕酮（LNG）的仅含孕激素避孕药对止血的影响。DSG降低了因子VII活性（p<0.05）和凝血酶原片段1+2（p<0.05），并增加了蛋白S（p<0.001）。LNG降低了因子VII活性（p<0.01）和纤溶酶原活性（p<0.01），并增加了组织纤溶酶原激活物（t-PA）（p<0.05）。在使用DSG的治疗后周期结束时，蛋白S（p<0.01）和t-PA（p<0.05）增加，纤溶酶原活性降低（p<0.05），而使用LNG时，t-PA增加（p<0.001），凝血酶原片段1+2（p<0.05）和纤溶酶原活性（p<0.001）降低。组间比较显示，在第7周期（p<0.01）和治疗后评估（p<0.05）时，DSG的抗凝参数蛋白S值更高，并且在第7周期（p<0.05）和治疗后（p<0.05）时，DSG的纤溶参数纤溶酶-抗纤溶酶复合物更高。两种制剂对止血都有相当且可能有益的影响，并且可能为有个人或家族静脉血栓栓塞疾病史的女性提供合适的激素避孕方法。
